Finnrick AFinnrick A Supplier
Safety & Side Effects
Trial data review
Retatrutide Side Effects: What the Trial Data Actually Shows (2026)
Retatrutide side effects from the Phase 2 NEJM trial and Phase 3 TRIUMPH-4 topline. Plain-English incidence, dose response, timeline, and research-use quality risks — without the hype.
Quick summary
- Retatrutide's most common side effects are gut-related: nausea, diarrhea, vomiting, and constipation. They peak right after each dose step-up and ease over a few weeks.
- There is a real but modest heart-rate increase at higher doses (about 5 to 7 beats per minute on average), which peaks around week 24 and then drifts back down.
- Retatrutide is not FDA-approved as of May 2026. Anything sold online as 'retatrutide peptide' is research-use only, and the FDA has explicitly said it cannot be legally compounded.
- Most common effect
- Nausea (up to ~60% at 12 mg)
- Pattern
- Dose-dependent, peaks at each step-up
- Heart-rate signal
- +5 to 7 bpm at higher doses
- Regulatory status
- Not FDA-approved (May 2026)
- Compounding
- Explicitly not allowed (FDA, Sep 2025)
- Evidence base
- Phase 2 NEJM + Phase 3 TRIUMPH-4 topline
Quick take
Retatrutide is a once-weekly investigational drug from Eli Lilly that hits three hunger and energy receptors at the same time: GLP-1, GIP, and glucagon. It is being studied for obesity, type 2 diabetes, sleep apnea, and knee osteoarthritis pain.
Most side effects show up in the stomach and gut. They get more common at higher doses, peak right after each step-up, then ease over a few weeks. The other notable signal is a modest rise in resting heart rate at higher doses.
Research-use only
This page is an educational reference, not medical advice. Retatrutide is not FDA-approved. The only legal way to take it in 2026 is inside an Eli Lilly clinical trial. The FDA explicitly disallowed retatrutide compounding and issued warning letters in September 2025.
- Nausea, diarrhea, vomiting, and constipation are the four most common side effects in every published trial.
- Heart rate goes up about 5 to 7 beats per minute on the higher doses, then drifts back down by weeks 36 to 48.
- Skin sensitivity (tingling, pressure pain, tenderness) showed up in roughly 7% of Phase 2 participants.
- Serious events were rare and matched placebo (4% each) in Phase 2 — including pancreatitis and gallbladder events.
- Long-term safety is not yet fully known. The first dedicated cardiovascular outcomes trial (TRIUMPH-Outcomes) is still running.
Retatrutide supplies
Use this as a research-use shopping checklist after reviewing the side-effect and monitoring context. It does not replace dose math, vial instructions, sterile handling guidance, lab interpretation, or medical advice.
Retatrutide Shopping Cards
PEPPAL applies to eligible supplier checkout links when supported by the supplier.
Why choose Peptide Partners?Finnrick BFinnrick B Supplier
Orbitrex Retatrutide
View RetatrutideBlood TestAt-Home Blood Test
SiPhox Health At-Home Blood Test
View Blood TestInjection Supplies
Disclosure: supply links may earn PepPal a commission at no cost to you.
What to verify before checkout
Use the supplier page, testing documents, and lab plan as the source of truth.
Product match
Confirm the product is retatrutide and that the vial size matches your research plan.
Batch documentation
Match the COA or testing record to the exact product and lot where the supplier makes that available.
Blood work
Arrange baseline and follow-up labs before interpreting GLP-1 research outcomes or side-effect patterns.
Injection supplies
Use fresh syringes, prep pads, and sharps disposal supplies for each handling session.
For reconstitution math, syringe units, and protocol-level instructions, use the retatrutide protocol instead of this shopping checklist.
The most common retatrutide side effects
Across both the Phase 2 NEJM trial (Jastreboff et al., 2023) and the Phase 3 TRIUMPH-4 topline reported by Eli Lilly in December 2025, four gut-related side effects show up the most. They are dose-dependent, meaning higher doses cause them more often.
Most common retatrutide side effects, by dose (Phase 2 NEJM data, 48 weeks)
Side effect
Nausea
1 mg
~14%
4 mg
~27%
8 mg
~42%
12 mg
~60%
Placebo
~9%
Side effect
Diarrhea
1 mg
~9%
4 mg
~21%
8 mg
~27%
12 mg
~33%
Placebo
~11%
Side effect
Vomiting
1 mg
~6%
4 mg
~19%
8 mg
~21%
12 mg
~26%
Placebo
~3%
Side effect
Constipation
1 mg
~11%
4 mg
~16%
8 mg
~16%
12 mg
~16%
Placebo
~6%
Side effect
Skin sensitivity
1 mg
~1-2%
4 mg
~3-4%
8 mg
~6%
12 mg
~7%
Placebo
~1%
Side effect
Hypersensitivity (rash, itching)
1 mg
~3%
4 mg
~6%
8 mg
~10%
12 mg
~13%
Placebo
~3%
Numbers are rounded approximations of published Phase 2 results. Phase 3 TRIUMPH-4 (12 mg arm) reported similar headline numbers: nausea ~43%, diarrhea ~33%, constipation ~25%, and vomiting ~21%.
What these numbers mean in plain English
At the 1 mg starting dose, most people felt only mild stomach changes. At 12 mg — the dose used to produce the headline 24% to 28% body-weight reductions — more than half of trial participants felt nausea at some point. Most of it was mild to moderate, and most of it eased without stopping the drug.
About 6% to 16% of participants on retatrutide stopped the drug because of side effects, mostly gut-related. Zero placebo participants stopped for that reason. That stop rate is similar to what semaglutide and tirzepatide trials reported.
How long retatrutide side effects last
This is one of the most-searched questions about retatrutide, and the answer depends on which effect you mean. The Phase 2 trial tracked timing carefully, so we can give specific answers instead of guesses.
When retatrutide side effects start, peak, and fade
Effect
Nausea, diarrhea, vomiting
When it starts
Within days of a dose step-up
When it peaks
First 1-2 weeks after each step
When it eases
Usually within 2-4 weeks at the new dose
Effect
Constipation
When it starts
Within the first few weeks of treatment
When it peaks
Variable, usually low-grade
When it eases
Often persists through the cycle but stays mild
Effect
Heart-rate increase
When it starts
First few weeks
When it peaks
Around week 24
When it eases
Drifts back toward baseline by weeks 36-48
Effect
Skin sensitivity
When it starts
Variable, can be early or mid-cycle
When it peaks
Often around mid-trial
When it eases
Usually resolves; some lingered through 48 weeks
Effect
Injection-site reactions
When it starts
Hours after a dose
When it peaks
Within the first day
When it eases
Usually within a few days
Retatrutide has a half-life of about 6 days. That is why each dose step is held for about 4 weeks in trials — it takes around 2 weeks at any new dose for blood levels to stabilize.
The general pattern: each dose step-up causes a fresh wave of gut symptoms that fade as the body adjusts. The heart-rate change is the one effect that builds up slowly over months and then improves on its own without dropping the dose.
Heart rate, blood pressure, and cardiovascular signals
Retatrutide raises resting heart rate at higher doses. In the Phase 2 trial, the average rise at 12 mg was about 6.7 beats per minute, with a typical range of 5 to 10 bpm across the higher dose groups. The rise peaked around week 24 and then drifted back down toward baseline by weeks 36 to 48.
This is slightly larger than the heart-rate rise reported for semaglutide (around 3 to 4 bpm in STEP trials) and tirzepatide (around 3 to 5 bpm in SURMOUNT-1). The glucagon receptor activation is the likely reason — glucagon directly increases cardiac output and heart rate.
What the cardiovascular data shows so far
- Blood pressure went down, not up. Phase 2 reported drops of roughly 10 mmHg systolic and 4-5 mmHg diastolic at 12 mg by week 48.
- Lipid profile improved. Triglycerides fell 35-40%, non-HDL cholesterol fell 13-18%, and HDL rose 5-8%.
- Arrhythmias were reported in 2-11% of retatrutide groups vs. 2% on placebo. None were classified as serious.
- No increase in heart attack or stroke has been reported in the Phase 2 data — but Phase 2 was not powered to detect rare cardiovascular events.
- TRIUMPH-Outcomes, the dedicated cardiovascular outcomes trial, is still running. Final results are expected around 2027-2028.
Phase 2 excluded high-risk hearts
Phase 2 trials generally exclude people with significant cardiovascular disease. That means the Phase 2 safety numbers do not automatically transfer to people with heart failure or recent cardiac events.
Less common side effects worth knowing about
Beyond the four main gut effects and the heart-rate signal, the published retatrutide trials reported a handful of other issues at lower rates.
Skin sensitivity (~7%)
Tingling, tenderness, pain when touched, or sensitivity to pressure or heat. Reported at roughly 7% on retatrutide vs. 1% on placebo. Phase 3 TRIUMPH-4 also reported dysesthesia signals in the 9 mg and 12 mg arms.
Injection-site reactions (~5-7%)
Redness, swelling, itching, or mild bruising at the site. Usually resolves in a few days. Rotating sites helps.
Hypersensitivity (3-13%)
Rash, hives, or itching at higher doses. Almost always mild and reversible. No anaphylaxis cases in published Phase 2 data.
Pancreatitis (rare)
One acute pancreatitis case at 12 mg in Phase 2. Asymptomatic rises in amylase and lipase were more common. This is a known class concern for all GLP-1 drugs.
Gallbladder events (rare)
Reported at rates similar to placebo in Phase 2. Rapid weight loss is an independent risk factor for gallstones, which makes attribution tricky.
Fatigue and decreased appetite
Decreased appetite was reported in around 14% at 12 mg. That is part of the mechanism more than an unwanted effect. Fatigue is occasionally reported but is not a primary signal in the published data.
Things people search for that did not show up as signals
- Cancer: No cancer signal has been reported in published retatrutide trials. The GLP-1 class has a theoretical thyroid C-cell tumor concern in rodent studies, which is why approved GLP-1 drugs carry a boxed warning. Retatrutide is not approved, so it has no boxed warning yet — but the class concern applies.
- Hair loss: Hair loss was not flagged as a primary signal in Phase 2. However, rapid weight loss of any cause can trigger telogen effluvium (a temporary hair-shedding response). Anecdotal reports of thinning hair on retatrutide are most likely tied to rapid weight loss rather than the drug itself.
- Mood changes: The published trials did not report a meaningful depression or suicidality signal. The FDA has investigated the broader GLP-1 class for this and has not found a clear link.
Research-use retatrutide is a separate risk
Everything above is based on pharmaceutical-grade retatrutide given inside a controlled Eli Lilly trial. That is not what is being sold online as 'retatrutide peptide.' The trial product and the research-use product are not the same thing, and the safety data does not automatically transfer.
What the FDA actually said
On September 9, 2025, the FDA issued more than 40 warning letters to telehealth pharmacies and compounders. Retatrutide was specifically named. The FDA stated: 'Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.'
The FDA also warned about products labeled 'for research purposes' or 'not for human consumption' that are being sold with dosing instructions aimed at human use. The agency said these products are of unknown quality and may be harmful.
What the quality risk actually looks like
- Identity: The vial may not contain retatrutide at all, or may contain a related peptide at the wrong concentration.
- Purity: Manufacturing impurities can include solvents, byproducts, and bacterial residue.
- Potency: Stated milligrams per vial may not match actual content, which makes any side-effect rate comparison to the published trial data meaningless.
- Storage: Improper shipping (warm packages, no cold packs) can degrade the peptide before it ever reaches you.
- Counterfeit: Some sellers are not legal compounders at all — they are counterfeit operations using non-sterile manufacturing.
If anyone is researching retatrutide outside a Lilly trial, the side-effect profile from the published trials is a baseline only. The actual product may carry additional, unknown risks. PepPal does not endorse using research-use peptides for human consumption.
Retatrutide vs. semaglutide vs. tirzepatide side effects
All three drugs share the same core side-effect pattern (nausea, diarrhea, vomiting, constipation) because they all activate GLP-1. Retatrutide adds GIP and glucagon receptor activity, which slightly changes the safety profile.
Side-effect profile comparison (high-dose arms)
Side effect
Nausea
Semaglutide 2.4 mg
~44%
Tirzepatide 15 mg
~33%
Retatrutide 12 mg
~60% (Phase 2) / ~43% (Phase 3)
Side effect
Diarrhea
Semaglutide 2.4 mg
~32%
Tirzepatide 15 mg
~22%
Retatrutide 12 mg
~33%
Side effect
Vomiting
Semaglutide 2.4 mg
~25%
Tirzepatide 15 mg
~12%
Retatrutide 12 mg
~21-26%
Side effect
Heart rate change
Semaglutide 2.4 mg
+3-4 bpm
Tirzepatide 15 mg
+3-5 bpm
Retatrutide 12 mg
+5-7 bpm
Side effect
Discontinuation for side effects
Semaglutide 2.4 mg
~7%
Tirzepatide 15 mg
~6-7%
Retatrutide 12 mg
~6-16%
Numbers approximated from published STEP-1, SURMOUNT-1, and retatrutide Phase 2 and Phase 3 TRIUMPH-4 data. Cross-trial comparisons are imperfect.
Retatrutide's overall side-effect profile is broadly in the same neighborhood as semaglutide and tirzepatide. It tends to run slightly higher on gut symptoms and heart-rate change, mostly because the 12 mg target dose is more aggressive and because glucagon activity adds a heart-rate signal that pure GLP-1 drugs do not have.
Comparing the three GLP-1-class drugs in more depth?
PepPal's full comparison guide breaks down efficacy, dosing, and access for all three.
Read the full comparisonRed flags that mean stop and seek care
Most retatrutide side effects in the trials were mild to moderate and faded with time. A small number are worth treating as same-day medical issues regardless of how the drug was obtained.
These symptoms need urgent attention
Seek medical care the same day for any of these. Do not wait to see if they pass on their own.
- Severe stomach pain that spreads to the back, with or without vomiting — possible pancreatitis.
- Vomiting that does not stop within 24 hours, or signs of dehydration.
- Yellowing of the skin or eyes, dark urine, or pale stools — possible liver or gallbladder issue.
- Sudden swelling of the face, lips, or throat; difficulty breathing; or widespread hives — possible serious allergic reaction.
- Chest pain, fast or irregular heartbeat that does not settle, or fainting.
- Severe upper-right abdominal pain with fever or nausea — possible gallbladder attack.
Anyone using a research-use product should have an even lower threshold to seek care, because the contents and concentration of those vials are not verified.
Retatrutide's current regulatory status
As of May 18, 2026, retatrutide is not FDA-approved. It is in Phase 3 development through Eli Lilly's TRIUMPH program. The first major Phase 3 readout, TRIUMPH-4 (obesity plus knee osteoarthritis), was announced in December 2025. The remaining Phase 3 readouts are expected through 2026 and 2027.
FDA approval is anticipated around 2027 under a moderate timeline, assuming the rest of the TRIUMPH readouts support it and Eli Lilly files a New Drug Application.
FDA actions on retatrutide compounding and sales
- April 2025: FDA issued formal letters confirming retatrutide is not eligible for 503A or 503B compounding because it is not in a USP/NF monograph, is not a component of an approved drug, and is not on the shortage list.
- September 9, 2025: FDA issued 40+ warning letters to telehealth pharmacies and compounders. Retatrutide was specifically cited.
- Ongoing 2026: FDA continues to publish warnings about retatrutide products sold online as 'research peptides' or 'not for human consumption' but marketed for human use.
What this means in plain language
There is no legal commercial retatrutide. Pharmacies cannot legally compound it. The only legal way to receive real retatrutide in 2026 is to enroll in a Lilly clinical trial. Anything else is research-use only.
Before you research retatrutide further
If you are looking into retatrutide for your own research, a few PepPal resources can help you reason about it more carefully.
How do you get retatrutide?
Plain-English breakdown of clinical trials, grey-market access, and the legal status.
Semaglutide vs. tirzepatide vs. retatrutide
Side-by-side weight loss, mechanism, and access comparison for the three big GLP-1-class drugs.
Best peptides for fat loss
Broader category context — where retatrutide fits among other peptides being researched for weight management.
How to read a peptide COA
If you are evaluating any research-use product, this walks through the documentation to look for and the red flags that mean walk away.
Frequently Asked Questions
What are the side effects of retatrutide?
The four most common side effects in every published retatrutide trial are nausea, diarrhea, vomiting, and constipation. At the 12 mg target dose in Phase 2, nausea was reported in roughly 60% of participants. Less common effects include skin sensitivity (around 7%), injection-site reactions, mild hypersensitivity, and a modest rise in resting heart rate (around 5 to 7 beats per minute at higher doses).
How long do retatrutide side effects last?
Gut side effects like nausea and vomiting typically peak in the first 1 to 2 weeks after each dose step-up, then ease over 2 to 4 weeks at the new dose. The heart-rate rise builds up more slowly, peaks around week 24, and drifts back toward baseline by weeks 36 to 48. Injection-site reactions usually resolve in a few days. Some skin sensitivity reports persisted through the full 48-week Phase 2 trial.
What are the most common side effects of retatrutide?
Nausea, diarrhea, vomiting, and constipation. These are the same four effects seen across the entire GLP-1 drug class. Retatrutide tends to produce them at slightly higher rates than semaglutide or tirzepatide at the highest studied doses, because the 12 mg target is more aggressive and because the added glucagon activity contributes to a slightly different profile.
When do retatrutide side effects start?
Most gut side effects start within the first few days of a dose step-up. Retatrutide has a half-life of about 6 days, which means it takes about two weeks at any new dose for blood levels to stabilize. That is why each dose level is held for about 4 weeks in trials before moving up.
Does retatrutide cause heart problems?
Retatrutide raises resting heart rate at higher doses — about 5 to 7 beats per minute on average at 12 mg. That rise peaked around week 24 in Phase 2 and then drifted back down. Phase 2 also reported mild arrhythmias in 2 to 11% of participants vs. 2% on placebo, none classified as serious. No increase in heart attack or stroke has been reported. Phase 2 was not powered to detect rare cardiovascular events, so the dedicated cardiovascular outcomes trial (TRIUMPH-Outcomes, expected 2027-2028) is still important.
Does retatrutide cause cancer?
No cancer signal has been reported in published retatrutide trials. The broader GLP-1 class carries a theoretical thyroid C-cell tumor concern based on rodent studies, which is why approved GLP-1 drugs like Wegovy and Mounjaro have a boxed warning. Retatrutide is not approved, so it has no boxed warning yet, but the class concern applies until longer human data is available.
Does retatrutide cause hair loss?
Hair loss was not flagged as a primary signal in the Phase 2 NEJM trial. However, rapid weight loss of any cause can trigger temporary hair shedding (telogen effluvium). Anecdotal reports of thinning hair on retatrutide are most likely tied to fast weight loss rather than to the drug itself. The same pattern shows up with semaglutide and tirzepatide.
How can side effects of retatrutide be reduced in trials?
In clinical trials, slower titration helps. The Phase 2 trial showed that starting at 2 mg and stepping up more slowly produced fewer gut side effects than starting at 4 mg. Holding each dose for the full 4 weeks before stepping up — instead of rushing to the next dose — also reduced symptoms. PepPal does not publish personal-use dosing protocols; for protocol-focused research, see Peptide Dosing Protocols.
Is retatrutide FDA-approved as of 2026?
No. As of May 2026, retatrutide is still in Phase 3 trials through Eli Lilly's TRIUMPH program. FDA approval is anticipated around 2027 if the remaining Phase 3 readouts support it. The FDA has explicitly said retatrutide cannot be legally compounded and has issued more than 40 warning letters to compounders and telehealth pharmacies in September 2025.
Should I worry about the quality of retatrutide sold online?
Yes. Anything sold as 'retatrutide peptide' online is research-use only and not FDA-reviewed. The published Phase 2 and Phase 3 safety data is based on Eli Lilly's exact trial product, which is not what online sellers are shipping. Quality risks include wrong identity, wrong concentration, impurities, and improper shipping or storage. The FDA has warned consumers not to purchase these products. If you are evaluating any research-use supplier, see PepPal's supplier reviews and COA reading guide.
Is this page medical advice?
No. This page is an educational summary of the published retatrutide trial data and current FDA status. It is not medical advice and is not a recommendation to take retatrutide. The only legal way to receive real retatrutide in 2026 is through an Eli Lilly clinical trial.
Preferred supplier
Peptide PartnersNeed peptides? Start with a verified supplier.
PepPal's recommended source with current discount access and established testing standards.
3rd-party testedResearch-grade supplierHigh purity batches
Sources and research notes
- 1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine (2023)
- 2. Eli Lilly and Company Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Investor press release (TRIUMPH-4 topline) (2025)
- 3. U.S. Food and Drug Administration FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA.gov (2026)
- 4. U.S. Food and Drug Administration GLP-1 Solution Warning Letter (715883). FDA.gov enforcement (2025)
- 5. Drugs.com editorial (Puckey M, BPharm) Retatrutide Weight Loss Treatment. Drugs.com (2026)
- 6. Drugs.com editorial (Puckey M, BPharm) What is 'retatrutide peptide' being sold online? Drugs.com medical answers (2026)
- 7. Alshehri AA, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology (2024)
- 8. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet (2023)
- 9. Eli Lilly and Company Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. PMC / journal article (2025)
- 10. ClinicalTrials.gov TRIUMPH program retatrutide Phase 3 trial registry entries. ClinicalTrials.gov (NCT05882045, NCT05869903, NCT06354660) (2026)